Fellowships award successes

It is with great pride that we congratulate the CERC members who have recently been awarded scholarships.

First of all, Claude Bhérer and Raquel Cuella Martin have both been awarded the Research Scholars - Junior 1 bursary funded by the Fonds de Recherche du Québec en Santé (FRQS). This scholarship will finance part of their salary for 4 years, as well as some research expenses.

The FRQS also awarded scholarships to 3 students: Alyssa Green, who received a Master's Training Scholarship for 2 years, as well as Susannah Selber-Hnatiw and Amisha Minju, who received a Doctoral Training Scholarship for 4 years.

Finally, 2 other students were also successful in winning Canadian Institutes of Health Research scholarships: Irene Pender was awarded the Canada Graduate Scholarships-Master's (CGS-M) while Juliano Malizia won the CIHR Strategic Master's Award - Computational Biology and Health Data Sciences, both for one year.

Congratulations to all our successful applicants!

Chen-Yang Su wins the Best poster presentation at the HBHL Symposium on May 8-9, 2024

Congratulations to Chen-Yang Su, PhD student of the McGill CERC in Genomic Medicine for winning the Best poster presentation at the Healthy Brains Healthy Lives (HBHL) Symposium on May 8-9, 2024 !

You will find the abstract of his presentation below:

Authors
Chen-Yang Su, Sirui Zhou

Proteomics and metabolomics integration uncovers molecular signatures associated with neuroprotective signatures in post-acute SARS-CoV-2 infection

Introduction: Post-acute sequelae SARS-CoV-2 (PASC) is an emerging public health concern with heterogeneous manifestations. Among PASC symptoms, long-term neurological manifestations are particularly debilitating. Their molecular underpinning remains poorly understood. Here, we combined proteomics and metabolomics to address this issue.

Methods: Proteomic and metabolomic data were generated for 1,234 individuals from the Biobanque Québécoise de la COVID-19 (BQC19), which followed COVID-19 patients over two years. After quality control, 4,984 proteins and 943 metabolites were retained for analysis. Using 689 clinical entries from the BQC19, we defined broad neurological PASC (BNP) as any neurological manifestations, whereas refined neurological PASC (RNP) was defined as neurological complications that either recently appeared or deteriorated due to COVID-19. We then fitted single biomarker logistic regression models while adjusting for age at diagnosis and sex to determine the association of each protein or metabolite with BNP or RNP.

Results: A total of 381 and 65 cases with both proteomics and metabolomics data met our definition of BNP and RNP and were compared with 535 and 713 controls, respectively. A total of 1,416 and 734 proteins were found significantly associated with BNP and RNP, respectively, with 544 overlapping proteins. In addition, 158 and 130 metabolites were found significantly associated with BNP and RNP, respectively, with 53 overlapping metabolites. In particular, we identified phosphatidylethanolamine-binding protein 1 (PEBP1) as being protective against BNP (OR (95% CI) = 0.76 (0.66-0.87), FDR p = 0.002) and RNP (OR (95% CI) = 0.61 (0.46-0.81), FDR p = 0.014). Interestingly enough, previous studies suggested downregulation of PEBP1 may lead to Alzheimer’s disease. Moreover, PEBP1 functions as an enzyme for 1-palmitoyl-2-docosahexaenoyl-GPE, a phosphatidylethanolamine (PE) whose impairment may lead to neurodegenerative disorders, which is concordant with our finding that increased circulating PE is associated with decreased neurological PASC risk (BNP: OR (95% CI) = 0.78 (0.68-0.90), FDR p = 0.01; RNP: OR (95% CI) = 0.56 (0.41-0.75), FDR p = 0.006).

Conclusion: Here, we used an integrative bi-omics approach combining proteomics and metabolomics to provide new insight into the pathophysiological mechanisms underlying neurological PASC risk which, possibly, could point to new ways to treat this condition.

A focus on the work of Claude Bhérer on the founder effect in the McGill Reporter

On April 17, 2024, the McGill Reporter has decided to put Claude Bhérer's research in the spotlight ! Claude Bhérer and her team are studying the genomes of founder populations and their genetic diseases, including the Leigh Syndrome French Canadian type.

Claude Bhérer explains why she decided to study genetics, and the founder effect in particular. The interview presents the challenges of Claude's research and the benefits of genetic studies in finding new therapies for rare diseases such as Leigh Syndrome French Canadian type.

You will find the full interview here.

A CERC student won the McGill 3MT people choice !

The CERC team is very proud to announce a CERC student, Shamika Shenoy, won the People’s Choice at the McGill 3MT (3 Minute Thesis) Final Competition on April 3rd, 2024. Shamika is a first-year Ph.D. student in Human Genetics who joined the Cuella Martin Lab and the CERC team in September 2023.

With a mind brimming with questions about the human body’s intricate workings, she embarked on a quest to decode the secrets of our genetic code and its impact on human health. At Cuella Martin Lab, Shamika delves to understand genes involved in the DNA damage response pathways, particularly in cell cycle regulation, breast cancer development and our immune system’s adaptability.

If you want to know more, you will find below an abstract of Shamika’s thesis and the full event replay on Youtube.

Defining common and context-specific protein sequences in the repair of double-strand breaks via non-homologous end-joining.

Safeguarding genomic integrity is paramount for maintaining cellular homeostasis. To achieve this, cells have evolved a complex network of tightly interconnected pathways collectively known as the DNA damage response (DDR). The DDR is a guardian for detecting and repairing a wide array of DNA lesions, including the double-strand breaks (DSBs). Upon sensing a DSB, a cascade of signalling events is initiated to mark the lesion site and recruit the necessary repair machinery. Notably, non-homologous end joining (NHEJ) machinery predominantly repairs DSBs in non-dividing cells and those in the G1 phase of the cell cycle.

Additionally, NHEJ plays a crucial role in the programmed assembly of V(D)J gene segments in B- and T-cells and immunoglobulin class switch recombination in B-cells. The diverse nature of DSBs from blunt to staggered ends and in different contexts makes it crucial to identify these multifunctional NHEJ protein sequences involved in the repair. While extensive structure-function analyses of these genes have been conducted, only a limited number of separation-of-function (SOF) mutations have been identified to date. This knowledge gap is particularly prominent in newly discovered NHEJ factors and in proteins with expansive multidomain architectures. In this study, we propose a novel approach that harnesses the power of in situ deep mutagenesis, using CRISPR-dependent base editors, to unravel the structure-function relationships of NHEJ proteins. By systematically probing these proteins, we aim to define the common and context-specific protein features that govern DSB repair. Our findings promise to shed new light on the intricacies of the DDR, providing insights that could have far-reaching implications for therapeutic interventions aimed at preserving genomic integrity and combating diseases associated with DNA damage.

Photo credits: Genevieve Quinn.

Development of a new cost-effective genome sequencing method at McGill

The McGill CERC in Genomic Medicine is proud to announce the publication of an article in the NPJ Genomic Medicine, entitled “A cost-effective sequencing method for genetic studies combining high-depth whole exome and low-depth whole genome”. This work is a collaboration between the CERC and the the McGill Genome Centre Sequencing and C3G platforms, lead by Claude Bhérer (first author) and Daniel Taliun (last author), both Assistant Professors in the CERC team. They have developed a new sequencing method called WEGS (Whole Exome Genome Sequencing), cheaper than standard Whole genome sequencing. Please find the abstract below:

Whole genome sequencing (WGS) at high-depth (30X) allows the accurate discovery of variants in the coding and non-coding DNA regions and helps elucidate the genetic underpinnings of human health and diseases. Yet, due to the prohibitive cost of high-depth WGS, most large-scale genetic association studies use genotyping arrays or high-depth whole exome sequencing (WES). Here we propose a cost-effective method which we call “Whole Exome Genome Sequencing” (WEGS), that combines low-depth WGS and high-depth WES with up to 8 samples pooled and sequenced simultaneously (multiplexed). We experimentally assess the performance of WEGS with four different depth of coverage and sample multiplexing configurations. We show that the optimal WEGS configurations are 1.7–2.0 times cheaper than standard WES (no-plexing), 1.8–2.1 times cheaper than high-depth WGS, reach similar recall and precision rates in detecting coding variants as WES, and capture more population-specific variants in the rest of the genome that are difficult to recover when using genotype imputation methods. We apply WEGS to 862 patients with peripheral artery disease and show that it directly assesses more known disease-associated variants than a typical genotyping array and thousands of non-imputable variants per disease-associated locus.

Chen-Yang Su wins the Trainee Poster Excellence Award at the 1st Canadian Symposium on Long COVID on Sep 20-21, 2023

Congratulations to Chen-Yang Su, PhD student of the McGill CERC in Genomic Medicine for winning the Trainee Poster Excellence Award at the 1st Canadian Symposium on Long COVID on Sep 20-21, 2023 !

You will find the abstract of his poster below:

Combining proteomics and metabolomics to identify signatures protective of neurological consequences of post-acute SARS-CoV-2 infection.

Chen-Yang Su1,3*, Sirui Zhou2,3*

Introduction: Post-acute sequelae SARS-CoV-2 (PASC) has heterogeneous manifestations including debilitating long-term neurological symptoms.

Methods: We measured 4,984 proteins and 943 metabolites in 1,234 individuals from the Biobanque Québécoise de la COVID-19 (BQC19). Using 689 clinical entries, we defined Broad Neurological PASC (BNP) as any neurological manifestations and Refined Neurological PASC (RNP) as neurological complications that recently appeared or deteriorated due to COVID-19. We fitted single-biomarker logistic regression models adjusting for age and sex to determine the association of each biomarker with PASC outcomes.

Results: We compared 381 BNP and 65 RNP cases with both proteomics and metabolomics data with 535 and 713 controls, respectively. We found 1,416 and 734 proteins significantly associated with BNP and RNP, respectively, with 544 overlapping proteins. For metabolites, 158 and 130 were significantly associated with BNP and RNP, respectively, with 53 overlapping. We identified phosphatidylethanolamine-binding protein 1 (PEBP1) as being protective against BNP (OR: 0.76 (0.66-0.87), FDR p: 0.002) and RNP (OR: 0.61 (0.46-0.81), FDR p: 0.014). Interestingly, previous studies suggested downregulation of PEBP1 may lead to Alzheimer’s disease. Moreover, PEBP1 is an enzyme for 1-palmitoyl-2-docosahexaenoyl-GPE, a phosphatidylethanolamine (PE) whose impairment leads to neurodegenerative disorders, which is concordant with our finding that increased circulating PE is associated with decreased neurological PASC risk (BNP OR: 0.78 (0.68-0.90), FDR p: 0.01; RNP OR: 0.56 (0.41-0.75), FDR p: 0.006).

Conclusion: We used an integrative bi-omics approach to provide new insight into the pathophysiological mechanisms underlying neurological PASC risk which may point to new ways to treat this condition.

First CERC article published in Nature!

On Sep 20, 2023, the CERC team gathered to celebrate the first CERC article: From target discovery to clinical drug development with human genetics, published in Nature in August 2023. This article is a big milestone for the CERC program and we want to congratulate all the authors: Katerina Trajanoska, Claude Bhérer, Daniel Taliun, Sirui Zhou, J Brent Richards, Vincent Mooser.

You will find all the informations on the article here and its abstract below:

The substantial investments in human genetics and genomics made over the past three decades were anticipated to result in many innovative therapies. Here we investigate the extent to which these expectations have been met, excluding cancer treatments. In our search, we identified 40 germline genetic observations that led directly to new targets and subsequently to novel approved therapies for 36 rare and 4 common conditions. The median time between genetic target discovery and drug approval was 25 years. Most of the genetically driven therapies for rare diseases compensate for disease-causing loss-of-function mutations. The therapies approved for common conditions are all inhibitors designed to pharmacologically mimic the natural, disease-protective effects of rare loss-of-function variants. Large biobank-based genetic studies have the power to identify and validate a large number of new drug targets. Genetics can also assist in the clinical development phase of drugs-for example, by selecting individuals who are most likely to respond to investigational therapies. This approach to drug development requires investments into large, diverse cohorts of deeply phenotyped individuals with appropriate consent for genetically assisted trials. A robust framework that facilitates responsible, sustainable benefit sharing will be required to capture the full potential of human genetics and genomics and bring effective and safe innovative therapies to patients quickly.

New academic year starting, the CERC team keeps growing !

It’s a new academic year starting and the CERC team has welcomed eleven new members! Four new PhD students (Shamika Shenoy, Olivia Cardinal, Yumi Dille, Chen-Yang Su) and five MSc students (Alyssa Green, Irene Pender, Juliano Malizia, Julia Cabre-Romans and Wardah Masud) joined the PhD/MSc thesis program at the Department of Human Genetics. Matthew Schinwald from the Quantitative Life Sciences program is doing his rotation with the CERC team this Fall and finally, Tanja Sack joined the team as a new post-doc. To get better acquainted with these new members, please visit our Current Team page!

First CERC student to graduate

We want to congratulate Mohadese Sayahian Dehkordi, who officially passed her MSc thesis! Mohadese started her MSc in September 2021 and she is the first student of our team graduating!

Here are a few word of her supervisor, Daniel Taliun:
“In her MSc work, in addition to her work on other projects, Mohadese generated massive amounts of high-quality results, which are essential for our group. With her impeccable work ethic and courage, she wrote all these results in her thesis within one month!”

You can find more information on Mohadese here.

Advancing Equity in Genetics and Genomics in Canada (AEG2C)

On November 9th and 10th, 2022, we were pleased to organize an international two-day symposium on Equity, Diversity and Inclusion (EDI) in Genomics entitled: "Advancing Equity in Genetics and Genomics in Canada (AEG2C)".

This event was co-organized and supported by the McGill Canada Excellence Research Chair (CERC) in Genomic Medicine and the Canadian Institute for Health Research (CIHR) Institute of Genetics. We received additionnal support from Genome Canada and Génome Québec.

This symposium highlighted the importance and value of inclusion and diversity in genomics to advance our understanding of the mechanisms of diseases and to promote health equity. It also presented best practices for making the genomics research enterprise diverse, inclusive, and beneficial to all. Lessons learned from international research initiatives engaging with diverse populations were showcased, as well as those arising from genomic studies in Quebec and Canada.

You will find all the recorded sessions on this link: AEG2C 2022.